Sarepta Therapeutics,
Inc. SRPT, a developer of innovative RNA-based
therapeutics, today announced that the U.S. Food and Drug
Administration (FDA) has granted Fast Track status for the
development of its lead infectious disease drug candidates, AVI-7288
and AVI-7537, for the treatment of Marburg virus and Ebola virus,
respectively. Sarepta has been developing these platform-based
therapeutics under a U.S. Department of Defense (DoD) contract
managed by the Joint Project Manager Transformational Medical
Technologies (JPM-TMT) Project Management Office, a component of the
Joint Program Executive Office for Chemical and Biological Defense
(JPEO-CBD).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in